November 30, 2021 - Regulatory SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study
September 24, 2021 - Regulatory SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis
August 27, 2021 - Regulatory SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)
August 27, 2021 - Regulatory SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis
August 25, 2021 - Regulatory SynAct strengthens IP portfolio – Grant of key European patent covering AP1189
August 20, 2021 - Regulatory SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021
July 7, 2021 - Regulatory SynAct Pharma Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer
July 7, 2021 - Regulatory SynAct Pharma AB Announces Additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients and Reminds of Management Call to Discuss Results
July 2, 2021 - Regulatory SynAct Pharma Hosts Conference Call on Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients
June 30, 2021 - Regulatory SynAct Pharma AB Announces Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients
June 23, 2021 - Regulatory SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations
June 1, 2021 - Regulatory SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients
May 21, 2021 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021
May 14, 2021 - Regulatory SynAct Pharma AB: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.
May 12, 2021 - Regulatory SynAct Pharma partners with Örebro University to study cardiovascular disease
April 30, 2021 - Regulatory SynAct Pharma to participate at Kempen’s virtual Life Sciences Conference
April 13, 2021 - Regulatory SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version
March 18, 2021 - Regulatory SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version
March 1, 2021 - Regulatory SynAct Pharma’s CFO and board member sell shares to cover taxes on holdings
February 11, 2021 - Regulatory SynAct Pharma Names James Knight as Chief Business Officer – Already published in Swedish today
February 5, 2021 - Regulatory SynAct carries out a directed share issue and raises proceeds of SEK 80 million
February 4, 2021 - Regulatory SynAct explores the conditions for carrying out a directed share issue – English version – Published today 17.31 CET
February 4, 2021 - Regulatory SynAct Pharma prepares move to Nasdaq Stockholm – English version – Published today at 17.31 CET
January 11, 2021 - Regulatory Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB
